Towercrest Capital Management Aptevo Therapeutics Inc. Transaction History

Towercrest Capital Management

  • $630 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 10, 2022
SELL
$6.48 - $17.49 $1.37 Million - $3.69 Million
-211,227 Closed
0 $0
Q3 2021

Dec 10, 2021
BUY
$15.01 - $22.16 $3.17 Million - $4.68 Million
211,227 New
211,227 $3.26 Million

About Aptevo Therapeutics Inc.

APVO Quotes by TradingView
  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $25.2M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track This Portfolio

Track Towercrest Capital Management Portfolio

Follow Towercrest Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Towercrest Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Towercrest Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email